Daniel D. VonHoff

815 total citations
13 papers, 654 citations indexed

About

Daniel D. VonHoff is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Daniel D. VonHoff has authored 13 papers receiving a total of 654 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Oncology and 2 papers in Cancer Research. Recurrent topics in Daniel D. VonHoff's work include Cancer, Hypoxia, and Metabolism (2 papers), Cancer therapeutics and mechanisms (2 papers) and Nuclear Structure and Function (2 papers). Daniel D. VonHoff is often cited by papers focused on Cancer, Hypoxia, and Metabolism (2 papers), Cancer therapeutics and mechanisms (2 papers) and Nuclear Structure and Function (2 papers). Daniel D. VonHoff collaborates with scholars based in United States and Japan. Daniel D. VonHoff's co-authors include Laurence H. Hurley, Adam Siddiqui-Jain, Danzhou Yang, Takumi Kawabe, Donald Küfe, Keiichi Sakakibara, Gail Broder, J.T. Thigpen, Martee L. Hensley and Robert S. Negrin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Oncotarget.

In The Last Decade

Daniel D. VonHoff

13 papers receiving 629 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel D. VonHoff United States 10 366 205 89 89 58 13 654
Michael Cerra United States 11 647 1.8× 217 1.1× 106 1.2× 48 0.5× 81 1.4× 13 909
Carla Flandina Italy 13 302 0.8× 187 0.9× 64 0.7× 39 0.4× 138 2.4× 31 592
Lisa Iacono United States 14 320 0.9× 278 1.4× 200 2.2× 52 0.6× 67 1.2× 34 761
Brad Hirakawa United States 10 318 0.9× 133 0.6× 60 0.7× 25 0.3× 51 0.9× 18 566
Enrique Poradosu United States 10 308 0.8× 135 0.7× 29 0.3× 38 0.4× 39 0.7× 17 556
Christian Henninger Germany 15 246 0.7× 265 1.3× 75 0.8× 75 0.8× 104 1.8× 22 646
Alex Bell United Kingdom 10 354 1.0× 189 0.9× 71 0.8× 23 0.3× 59 1.0× 12 637
Christine Wittig Germany 7 396 1.1× 164 0.8× 91 1.0× 86 1.0× 163 2.8× 8 584
Hiromi Tanii Japan 12 340 0.9× 269 1.3× 57 0.6× 25 0.3× 43 0.7× 19 536
Teruaki Kimura Japan 16 321 0.9× 98 0.5× 37 0.4× 160 1.8× 41 0.7× 27 974

Countries citing papers authored by Daniel D. VonHoff

Since Specialization
Citations

This map shows the geographic impact of Daniel D. VonHoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel D. VonHoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel D. VonHoff more than expected).

Fields of papers citing papers by Daniel D. VonHoff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel D. VonHoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel D. VonHoff. The network helps show where Daniel D. VonHoff may publish in the future.

Co-authorship network of co-authors of Daniel D. VonHoff

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel D. VonHoff. A scholar is included among the top collaborators of Daniel D. VonHoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel D. VonHoff. Daniel D. VonHoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Mine, Naoki, Sayaka Yamamoto, Naoya Saito, et al.. (2017). CBP501 suppresses macrophage induced cancer stem cell like features and metastases. Oncotarget. 8(38). 64015–64031. 5 indexed citations
2.
3.
Greeno, Edward, Erkut Borazanci, Jon P. Gockerman, et al.. (2016). Phase I dose escalation and pharmokinetic study of a modified schedule of 14-o-phosphonooxymethyltriptolide.. Journal of Clinical Oncology. 34(4_suppl). TPS472–TPS472. 5 indexed citations
4.
Saito, Naoya, Keiichi Sakakibara, Jonathan M. Friedman, et al.. (2014). CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway. Molecular Cancer Therapeutics. 13(12). 3013–3023. 24 indexed citations
5.
Hahn, Tobias, Laurence H. Hurley, Daniel D. VonHoff, et al.. (2011). The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer. BMC Cancer. 11(1). 471–471. 18 indexed citations
6.
Sakakibara, Keiichi, Naoya Saito, Atsushi Suzuki, et al.. (2011). CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood. 118(14). 3922–3931. 103 indexed citations
7.
Kobayashi, Hidetaka, Sayaka Yamamoto, Hitoshi Sato, et al.. (2007). Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Molecular Cancer Therapeutics. 6(1). 147–153. 40 indexed citations
8.
Hurley, Laurence H., Daniel D. VonHoff, Adam Siddiqui-Jain, & Danzhou Yang. (2006). Drug Targeting of the c-MYC Promoter to Repress Gene Expression via a G-Quadruplex Silencer Element. Seminars in Oncology. 33(4). 498–512. 103 indexed citations
9.
Han, Heyou, et al.. (2006). Targeting Loss-of-Function Mutations in Tumor-Suppressor Genes as a Strategy for Development of Cancer Therapeutic Agents. Seminars in Oncology. 33(4). 513–520. 20 indexed citations
10.
Warner, Stephanie, Philip Gray, & Daniel D. VonHoff. (2006). Tubulin-Associated Drug Targets: Aurora Kinases, Polo-like Kinases, and Others. Seminars in Oncology. 33(4). 436–448. 37 indexed citations
11.
VonHoff, Daniel D., Philip Gray, & Tomislav Dragovich. (2006). Pursuing Therapeutic Targets That Are and Are Not There: A Tumor’s Context of Vulnerability. Seminars in Oncology. 33(4). 367–368. 1 indexed citations
12.
Hensley, Martee L., Celeste Lindley, Gail Broder, et al.. (1999). American Society of Clinical Oncology Clinical Practice Guidelinesfor the Use of Chemotherapy and Radiotherapy Protectants. Journal of Clinical Oncology. 17(10). 3333–3355. 264 indexed citations
13.
Legha, Sewa S., et al.. (1976). Neocarzinostatin (NSC 157365) a New Cancerostatic Compound. Oncology. 33(5-6). 265–270. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Cerra Breakdown of academic impact, for papers by Carla Flandina Breakdown of academic impact, for papers by Lisa Iacono Breakdown of academic impact, for papers by Brad Hirakawa Breakdown of academic impact, for papers by Enrique Poradosu Breakdown of academic impact, for papers by Christian Henninger Breakdown of academic impact, for papers by Alex Bell Breakdown of academic impact, for papers by Christine Wittig Breakdown of academic impact, for papers by Hiromi Tanii Breakdown of academic impact, for papers by Teruaki Kimura
Rankless by CCL
2026